| Market Capitalization (Millions $) |
10 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
2 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-2 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Xenetic Biosciences Inc is a biopharmaceutical company that focuses on the development of next-generation biologic drugs and technologies. The company uses its proprietary drug development platform, PolyXen, to improve the efficacy, safety, and half-life of therapeutic proteins and peptides.
Xenetic Biosciences has a range of product candidates in various stages of development, including oncology drugs, anemia treatments, and blood coagulation disorders. These products aim to address unmet needs in the market and provide innovative solutions for patients.
The company also collaborates with pharmaceutical partners to develop and commercialize its products, leveraging their expertise and resources. Xenetic Biosciences has a global presence and seeks to expand its product portfolio through strategic partnerships and acquisitions.
Overall, Xenetic Biosciences Inc aims to advance the field of biotechnology by developing novel and transformative therapies that can significantly impact patient health outcomes.
Company Address: 945 Concord Street Framingham 1701 MA
Company Phone Number: 778-7720 Stock Exchange / Ticker: NASDAQ XBIO
|
0.13% 